clinical trial · NCT07402876
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Primary Vitreoretinal LymphomaICM ADX-2191 injectionMonthly ADX-2191 injection
brief summary
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
started
Feb 1, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Feb 11, 2026
official title
A Prospective, Randomized, Double-masked, Dosing-frequency-controlled, Multicenter Clinical Trial Evaluating the Safety and Activity of Intravitreally Injected ADX-2191 (Methotrexate Injection USP) in Patients With Primary Vitreoretinal Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol